EBITDA (Quarterly)

EBITDA: Income before interest, taxes, depreciation and amortization.

ANI Pharmaceuticals, Inc. (ANIP) had EBITDA of $59.81M for the most recently reported fiscal quarter, ending 2026-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2026-03-31

Income Statement Financials
Revenue	$237.46M
Net Income	$29.49M
Cost of Goods Sold	$93.58M
Gross Profit	$143.88M
Operating Expenses	$198.57M
Operating Income	$38.89M
Non-Operating Income/Expense	$1.33M
Pre-Tax Income	$40.22M
Normalized Pre-Tax Income	$40.22M
Income after Taxes	$29.49M
Income from Continuous Operations	$29.49M
Consolidated Net Income/Loss	$29.49M
Normalized Income after Taxes	$29.49M
EBIT	$38.89M
EBITDA	$59.81M
Weighted-Average Shares Outstanding (Basic)	20.91M
Weighted-Average Shares Outstanding (Diluted)	21.54M
Earnings per Share (EPS) (Basic)	$1.31
Earnings per Share (EPS) (Diluted)	$1.28
Balance Sheet Financials
Current Assets	$747.08M
Property, Plant, and Equipment	$67.11M
Long-Term Assets	$674.89M
Total Assets	$1.42B
Current Liabilities	$239.51M
Long-Term Debt	$594.46M
Long-Term Liabilities	$620.16M
Total Liabilities	$859.67M
Common Equity	$562.30M
Tangible Shareholders Equity	$32.66M
Shareholders Equity	$562.30M
Common Shares Outstanding	22.89M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$58.38M
Cash Flow from Investing Activities	$-11.32M
Cash Flow from Financial Activities	$-21.62M
Beginning Cash	$285.62M
End Cash	$311.21M
Increase/Decrease in Cash	$25.59M
Stock-Based Compensation	$10.19M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	$0.00M
Fundamental Metrics & Ratios
Current Ratio	3.12
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.51
Debt to Equity Ratio	1.09
Gross Margin	60.59%
Operating Margin	16.38%
EBIT Margin	16.38%
EBITDA Margin	--
Pre-Tax Profit Margin	16.94%
Profit Margin	12.42%
Free Cash Flow	$52.30M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.17
Inventory Turnover	0.65
Receiveable Turnover	0.93
Days Sales in Receivables	96.81
Return on Equity	5.24%
Return on Tangible Equity	90.30%
Return on Assets	2.07%
Return on Investments	2.55%
Book Value Per Share	$24.57
Free Cash Flow per Share	$2.43
Operating Cash Flow per Share	$2.71

Data from Zacks Investment Research, Inc.